EMA Defends Redacting Humira Trial Reports

Clinical Trials Advisor
A A
The European Medicines Agency is defending its decision to redact certain clinical study reports for AbbVie’s Humira before releasing them to a researcher, setting up a test case for the EU’s new trial transparency policy.

To View This Article:

Login

Subscribe To Clinical Trials Advisor